Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
← catalyst calendarNCT03154697 · readout ≤ 1,595 d
Sponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2016 | actual | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2017-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sleep Disturbances in Smith-Magenis Syndrome
Intervention
- Other: Data collection of sleep disturbances in individuals with SMS
Primary outcome
what the primary-completion date above is the date OFNumber of individuals with Smith- Magenis syndrome
measured 5 years
Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed